Table 2.

Risk factors of postoperative use of antibiotics

	Postoperative non-use	Postoperative short-term use		Postoperative non-use	Postoperative long-term use
	Number	Number	OR (95% CI)	Number	Number	OR (95% CI)
Preoperative use
No	1473	182	Reference	1420	235	Reference
Yes	367	129	2.6 (2.0 to 3.5)	281	215	4.5 (3.5 to 5.7)
Age group
18–39	185	27	0.9 (0.5 to 1.5)	163	49	1.5 (0.9 to 2.3)
40–59	981	126	0.6 (0.5 to 0.9)	931	176	0.7 (0.5 to 0.9)
60−	674	158	Reference	607	225	Reference
Procedure
rpMUS	568	107	1.7 (1.1 to 2.7)	529	146	1.3 (0.9 to 1.9)
toMUS	849	123	Reference	782	190	Reference
Bulking	315	45	1.4 (0.9 to 2.0)	278	82	1.1 (0.8 to 1.5)
Others	108	36	3.1 (1.6 to 5.9)	112	32	1.5 (0.8 to 2.8)
Preoperative use of oestrogen*
No	1059	149	Reference	992	216	Reference
Yes	781	162	1.2 (0.9 to 1.6)	709	234	1.2 (0.9 to 1.5)
Comorbidity (CCI)
0	1328	184	Reference	1241	271	Reference
1–2	425	95	1.5 (1.1 to 2.0)	384	136	1.4 (1.1 to 1.8)
3+	87	32	3.1 (1.6 to 5.9)	76	43	1.5 (1.0 to 2.4)
Educational level†
Basic	775	142	Reference	702	215	Reference
Secondary	665	105	1.1 (0.8 to 1.5)	623	147	1.0 (0.7 to 1.1)
Higher	362	62	1.3 (0.9 to 2.0)	342	82	0.9 (0.6 to 1.3)
Annual income
Low	434	103	Reference	404	133	Reference
Middle	930	147	0.9 (0.6 to 1.2)	847	230	1.0 (0.8 to 1.3)
High	476	61	0.9 (0.6 to 1.4)	450	87	0.9 (0.6 to 1.3)
Year of surgery
1996–2006	363	96	1.4 (0.9 to 2.2)	352	107	0.9 (0.7 to 1.1)
2007–2008	692	99	Reference	628	163	reference
2009–2010	785	116	1.0 (0.8 to 1.4)	721	180	1.0 (0.8 to 1.4)

Results from multivariate logistic regression models on (1) short-term (0–60 days after surgery) and (2) long-term (61–356 days after surgery).

*Women with at least one redeemed prescription of oestrogen within 365 days preceding the date of surgery.

†Unknown highest attained educational level: 40 women.

CCI, Charlson comorbidity index; Post op, postoperative; rpMUS, retropubic mid-urethral sling; toMUS, trans-obturator mid-urethral sling.